West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

Original reporting
Published Aug 20, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation — source image
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The IRB approval enables real‑world data collection, which could validate the device's efficacy and drive broader adoption.

02

Market read

First‑report of a regulatory milestone for a niche med‑tech firm; may influence its stock and the cryoablation market.

03

What to watch

Potential competition from alternative ablation technologies and reimbursement uncertainties could temper upside.

Relevance 7/10Novelty 7/10Timing: patient enrollment expected in the coming weeks

Background

IceCure Medical's ProSense® system is the only FDA‑cleared cryoablation device for low‑risk breast cancer in women 70+. The ChoICE study will enroll up to 400 patients across 30 sites.

Company-level read

Ticker impact

$ICCMBullishMedium confidence
Context

IceCure Medical received IRB approval to start the ChoICE post‑marketing study for its ProSense® breast‑cancer cryoablation device.

Expected impact

Potential modest upside as the study enrollment begins, with longer‑term upside if data are favorable.

Evidence & confidence

IRB approval is a concrete new development, but commercial impact depends on patient enrollment and future trial results.

Market effects

May reinforce interest in minimally invasive cryoablation technologies across the med‑tech sector.

Highlights growth of breast‑cancer treatment options in the U.S. Midwest.

Supports broader adoption of cryoablation devices worldwide as more data become available.

Counterpoint

If enrollment lags or data are inconclusive, the approval could be a non‑event with limited price impact.

Key entities

  • IceCure Medical Ltd.

    Developer of the ProSense® cryoablation system.

  • West Cancer Center & Research Institute

    Site of the IRB approval and study enrollment.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.